Magnetic Resonance - Technology Information Portal Welcome to MRI Technology
Info
  Sheets

Out-
      side
 



 
 'Gadoterate Meglumine' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Gadoterate Meglumine' found in 1 term [] and 3 definitions []
1 - 4 (of 4)     
Result Pages : [1]
Searchterm 'Gadoterate Meglumine' was also found in the following service: 
spacer
News  (2)  
 
Gadoterate MeglumineInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
Short name: Gd-DOTA, generic name: Gadoterate meglumine
Dotarem / [ Artirem® ] A paramagnetic MRI contrast agent for intravenous use. This agent is used as a routine clinical tool to reveal anatomical details in vivo and to detect lesions for diagnosis.

See also Contrast Agents.
spacer
 
• Share the entry 'Gadoterate Meglumine':  Facebook  Twitter  LinkedIn  
 
• Related Searches:
    • Contrast Agents
    • Paramagnetic Contrast Agents
    • Guerbet S.A.
    • Paramagnetic Substance
    • Dotarem®
 
Further Reading:
  News & More:
FDA Approves First Macrocyclic and Ionic Gadolinium-Contrast Agent for MRI
Friday, 22 March 2013   by www.itnonline.com    
MRI Resources 
Fluorescence - MRI Reimbursement - MRCP - Artifacts - Crystallography - Mobile MRI
 
Artirem®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Artirem®, the arthrography-specific contrast agent for MRI is a dilute form of Dotarem® with a less concentration of Gd (1:200). Artirem® has to be injected directly into the joints for better visualization and delimitation, of the ligament and tendon structures in particular.
Drug Information and Specification
NAME OF COMPOUND
DEVELOPER
CENTRAL MOIETY
Gd2+
CONTRAST EFFECT
T1, Predominantly positive enhancement
r1=3.4, r2=4.8, B0=1.0T
PHARMACOKINETIC
Intravascular, extracellular, renal excretion
CONCENTRATION
0,0025 mmol/ml
PREPARATION
Finished product
INDICATION
Arthrography
DEVELOPMENT STAGE
For sale
DISTRIBUTOR
See below
PRESENTATION
Pre-filled syringes of 20 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT
STAGE
DISTRIBUTOR
EU
for sale
France, Switzerland
Artirem®
for sale
Australia
for sale
spacer

• View the DATABASE results for 'Artirem®' (4).Open this link in a new window

 
Further Reading:
  News & More:
EMA's final opinion confirms restrictions on use of linear gadolinium agents in body scans
Friday, 21 July 2017   by www.ema.europa.eu    
MRI Resources 
Case Studies - Stent - Non-English - IR - Implant and Prosthesis - General
 
Contrast AgentsForum -
related threadsInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Contrast agents are chemical substances introduced to the anatomical or functional region being imaged, to increase the differences between different tissues or between normal and abnormal tissue, by altering the relaxation times. MRI contrast agents are classified by the different changes in relaxation times after their injection.
Positive contrast agents cause a reduction in the T1 relaxation time (increased signal intensity on T1 weighted images). They (appearing bright on MRI) are typically small molecular weight compounds containing as their active element Gadolinium, Manganese, or Iron. All of these elements have unpaired electron spins in their outer shells and long relaxivities.
Some typical contrast agents as gadopentetate dimeglumine, gadoteridol, and gadoterate meglumine are utilized for the central nervous system and the complete body; mangafodipir trisodium is specially used for lesions of the liver and gadodiamide for the central nervous system.
Negative contrast agents (appearing predominantly dark on MRI) are small particulate aggregates often termed superparamagnetic iron oxide (SPIO). These agents produce predominantly spin spin relaxation effects (local field inhomogeneities), which results in shorter T1 and T2 relaxation times.
SPIO's and ultrasmall superparamagnetic iron oxides (USPIO) usually consist of a crystalline iron oxide core containing thousands of iron atoms and a shell of polymer, dextran, polyethyleneglycol, and produce very high T2 relaxivities. USPIOs smaller than 300 nm cause a substantial T1 relaxation. T2 weighted effects are predominant.
A special group of negative contrast agents (appearing dark on MRI) are perfluorocarbons (perfluorochemicals), because their presence excludes the hydrogen atoms responsible for the signal in MR imaging.

The design objectives for the next generation of MR contrast agents will likely focus on prolonging intravascular retention, improving tissue targeting, and accessing new contrast mechanisms. Macromolecular paramagnetic contrast agents are being tested worldwide. Preclinical data shows that these agents demonstrate great promise for improving the quality of MR angiography, and in quantificating capillary permeability and myocardial perfusion.
Ultrasmall superparamagnetic iron oxide (USPIO) particles have been evaluated in multicenter clinical trials for lymph node MR imaging and MR angiography, with the clinical impact under discussion. In addition, a wide variety of vector and carrier molecules, including antibodies, peptides, proteins, polysaccharides, liposomes, and cells have been developed to deliver magnetic labels to specific sites. Technical advances in MR imaging will further increase the efficacy and necessity of tissue-specific MRI contrast agents.

See also Adverse Reaction and Nephrogenic Systemic Fibrosis.

See also the related poll result: 'The development of contrast agents in MRI is'
 
Images, Movies, Sliders:
 Delayed Myocardial Contrast Enhancement from Infarct  Open this link in a new window
      

Courtesy of  Robert R. Edelman
 Left Circumflex Ischemia First-pass Contrast Enhancement  Open this link in a new window
 MR Colonography Gadolinium per Rectum  Open this link in a new window
      

Courtesy of  Robert R. Edelman
 CE MRA of the Aorta  Open this link in a new window
    
SlidersSliders Overview

 
Radiology-tip.comradContrast Agents,  Safety of Contrast Agents
spacer
Medical-Ultrasound-Imaging.comUltrasound Contrast Agents,  Ultrasound Contrast Agent Safety
spacer

• View the DATABASE results for 'Contrast Agents' (122).Open this link in a new window


• View the NEWS results for 'Contrast Agents' (25).Open this link in a new window.
 
Further Reading:
  Basics:
Analysis of MRI contrast agents
Thursday, 17 November 2022   by www.sciencedaily.com    
New guidelines urge caution on use of contrast agents during MR scans
Tuesday, 8 August 2017   by www.dotmed.com    
New Study Sheds Light on Safety of Gadolinium-Based Contrast Agents
Wednesday, 29 November 2017   by www.empr.com    
A safer approach for diagnostic medical imaging
Monday, 29 September 2014   by www.eurekalert.org    
Manganese-based MRI contrast agents: past, present and future
Friday, 4 November 2011   by www.ncbi.nlm.nih.gov    
  News & More:
Brain imaging method may aid mild traumatic brain injury diagnosis
Tuesday, 16 January 2024   by parkinsonsnewstoday.com    
A Targeted Multi-Crystalline Manganese Oxide as a Tumor-Selective Nano-Sized MRI Contrast Agent for Early and Accurate Diagnosis of Tumors
Thursday, 18 January 2024   by www.dovepress.com    
FDA Approves Gadopiclenol for Contrast-Enhanced Magnetic Resonance Imaging
Tuesday, 27 September 2022   by www.pharmacytimes.com    
How to stop using gadolinium chelates for magnetic resonance imaging: clinical-translational experiences with ferumoxytol
Saturday, 5 February 2022   by www.ncbi.nlm.nih.gov    
Estimation of Contrast Agent Concentration in DCE-MRI Using 2 Flip Angles
Tuesday, 11 January 2022   by pubmed.ncbi.nlm.nih.gov    
Manganese enhanced MRI provides more accurate details of heart function after a heart attack
Tuesday, 11 May 2021   by www.news-medical.net    
Gadopiclenol: positive results for Phase III clinical trials
Monday, 29 March 2021   by www.pharmiweb.co    
Gadolinium-Based Contrast Agents Hypersensitivity: A Case Series
Friday, 4 December 2020   by www.dovepress.com    
Polysaccharide-Core Contrast Agent as Gadolinium Alternative for Vascular MR
Monday, 8 March 2021   by www.diagnosticimaging.com    
Water-based non-toxic MRI contrast agents
Monday, 11 May 2020   by chemistrycommunity.nature.com    
New method to detect early-stage cancer identified by Georgia State, Emory research team
Friday, 7 February 2020   by www.eurekalert.org    
Researchers Brighten Path for Creating New Type of MRI Contrast Agent
Friday, 7 February 2020   by www.newswise.com    
Manganese-based MRI contrast agent may be safer alternative to gadolinium-based agents
Wednesday, 15 November 2017   by www.eurekalert.org    
Sodium MRI May Show Biomarker for Migraine
Friday, 1 December 2017   by psychcentral.com    
A natural boost for MRI scans
Monday, 21 October 2013   by www.eurekalert.org    
For MRI, time is of the essence A new generation of contrast agents could make for faster and more accurate imaging
Tuesday, 28 June 2011   by scienceline.org    
Searchterm 'Gadoterate Meglumine' was also found in the following service: 
spacer
News  (2)  
 
Dotarem®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Dotarem® is a paramagnetic ionic MRI contrast agent. Extracellular contrast agents like Dotarem®, can be bolus injected because of the relatively low rate of side effects. This contrast medium is useable to enhance signal intensity in magnetic resonance imaging for intracranial and spinal lesions with an abnormal blood brain barrier or abnormal vascularity, and in whole body imaging.

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.
Drug Information and Specification
NAME OF COMPOUND
DEVELOPER
CENTRAL MOIETY
Gd2+
CONTRAST EFFECT
T1, Predominantly positive enhancement
r1=3.4, r2=4.8, B0=1.0T
PHARMACOKINETIC
Intravascular, extracellular, renal excretion
1350 mosm/kgH2O
CONCENTRATION
0.5 mol/L
DOSAGE
0.1 mmol/kg / 0.2mL/kg
PREPARATION
Finished product
INDICATION
Neuro/whole body
DEVELOPMENT STAGE
For sale
DISTRIBUTOR
See below
PRESENTATION
Vials of 5, 10, 15, 20mL
Pre-filled syringes of 15 and 20 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT
STAGE
DISTRIBUTOR
EU
for sale
France, Switzerland
Artirem®
for sale
Australia
for sale
spacer

• View the DATABASE results for 'Dotarem®' (7).Open this link in a new window

 
Further Reading:
  Basics:
Important Drug Warning for Gadolinium-Based Contrast Agents
Wednesday, 12 September 2007   by www.ismrm.org    
  News & More:
RSNA Statement on Gadolinium-Based MR Contrast Agents
Thursday, 1 February 2018   by www.rsna.org    
EMA's final opinion confirms restrictions on use of linear gadolinium agents in body scans
Friday, 21 July 2017   by www.ema.europa.eu    
MRI Resources 
Sequences - Stimulator pool - Mobile MRI - Pacemaker - MRI Technician and Technologist Jobs - Spectroscopy pool
 
     1 - 4 (of 4)     
Result Pages : [1]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?    



MRI is trending to low field magnets :
reduced costs will lead to this change 
AI will close the gap to high field 
only in remote areas 
is only temporary 
never 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • Medical-Ultrasound-Imaging • 
Copyright © 2003 - 2024 SoftWays. All rights reserved. [ 28 March 2024]
Terms of Use | Privacy Policy | Advertising
 [last update: 2024-02-26 03:41:00]